On Thursday, November 3, before the opening of the stock market, Intellia Therapeutics (NASDAQ: NTLA) will announce the monetary outcomes of its most recent quarterly report. The majority opinion held by market analysts is that Intellia Therapeutics will report a loss of $1.31 per share for the period ending in the fourth quarter.

On Thursday, August 4, the most recent quarterly results report for Intellia Therapeutics (NASDAQ: NTLA) was made public and presented to the investing community. The market’s estimate for the company’s profits per share for the quarter was $1.31, so the actual profit reported by the company was $1.33, which was ($0.02) lower than the estimate. The company’s sales for the quarter brought in $14 million, a significant increase from the $9.50 million that was the consensus expectation. In their most recent financial report, Intellia Therapeutics had a negative return on equity of 40.23% and a negative net margin of 883.17%. These figures can be found in the table below.
Compared to the previous fiscal year, the current year saw a revenue increase of 115.4%. However, earnings per share for the company came in at a loss of ($1.01) during the same period the previous year. Business analysts believe that Intellia Therapeutics will earn $6 per share in the current and future fiscal years. This is the consensus among business analysts.
The price of a share of NTLA fell by $0.46 during trading on Friday, bringing the stock to a new level of $51.70. The number of shares traded in the company was 3,500, a significantly lower volume than the typical 966,655 shares. The company’s stock is currently trading at $57.64, higher than its moving averages for the past 50 and 200 days, which are $55.52, respectively. The company’s market capitalization is currently valued at $3.93 billion, while its price-to-earnings ratio is currently valued at-9.89 and its beta value is currently 1.95. During the previous year, the price of Intellia Therapeutics fluctuated between the ranges of $37.08 and $143.92, with a low of $37.08 and a high of $143.92.
There have been several analyst reports in which NTLA has been mentioned. On October 12, which was a Wednesday, Intellia Therapeutics was added to the scope of coverage that StockNews.com provides. They suggested that customers “sell” the company to the company. In a research note published on October 11, Morgan Stanley announced that it would start covering shares of Intellia Therapeutics. They assigned the business an “overweight” rating and determined that a price objective of $85.00 was appropriate. In a report released on Monday, September 19, the investment firm SVB Leerink raised their price objective on Intellia Therapeutics stock from $152.00 to $158.00 and gave the stock an “outperform” rating. The addition of Intellia Therapeutics to Citigroup’s coverage was detailed in a report made available to the public on September 1. They suggested that investors “sell” their shares in the company, and they projected that the stock’s price would reach $50.00 within the next month. Finally, in a piece of research released on Tuesday, August 9, Credit Suisse Group announced an increase in the target price they set for Intellia Therapeutics to $101.00. This was the last but not the least of their announcements. Fifteen analysts are in favor of buying the stock, one analyst who is in favor of keeping the stock, and two experts who are in favor of selling the stock. According to the data provided by Bloomberg.com, the company’s current consensus target price is $113.59, and the average recommendation for it is “Moderate Buy.”

Shares of NTLA have been bought and sold by several hedge funds and other institutional investors over the most recent few months. Penserra Capital Management LLC spent $97,000 acquiring a position in Intellia Therapeutics during the first three months of 2018. Point72 Hong Kong Ltd. spent $165,000 over the first three months of 2018 to acquire a new position in Intellia Therapeutics. Dynamic Technology Lab Private Ltd. acquired a new stake in Intellia Therapeutics during the first three months of 2018 at approximately 252 thousand dollars. First Republic Investment Management Inc. initiated a new position in Intellia Therapeutics during the second quarter by investing approximately $283,000. And finally, during the first three months of this year, the Canada Pension Plan Investment Board made an investment in Intellia Therapeutics worth $307,000. The majority of the company’s stock is owned by large financial institutions, which account for 88.18 percent of the total.

The creation of new medicines is Intellia Pharmaceuticals, Inc.’s primary focus, even though the company is best known for its expertise in modifying genomes. NTLA-2001 and NTLA-2002 are two in vivo programs the company is working on. NTLA-2001 is undergoing a Phase 1 clinical trial for the treatment of transthyretin amyloidosis, and NTLA-2002 is undergoing a Phase 1 clinical trial for the treatment of hereditary angioedema. Both of these programs are being conducted by the company. The company is in the process of developing these two different programs. In addition, programs focus on the liver and treat hemophilia A and hemophilia B, as well as hyperoxaluria type 1 and alpha-1 antitrypsin deficiency. These conditions are all related to bleeding disorders.

The post Intellia Therapeutics (NTLA) is set to release earnings on Thursday. appeared first on Best Stocks.